Compare Abbott Laboratories (ABT) vs Baidu Inc (BIDU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Baidu Inc — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while Baidu Inc trades at $117.8 (market cap $38.39B). The key difference: Abbott Laboratories is far larger — about 4.3× Baidu Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Baidu Inc pays none. Which is the better fit depends on your goals.
| ABT | BIDU | |
|---|---|---|
Market Cap | $166.94B | $38.39B |
Sector | Health | Media |
52-Week High | $136.62 | $162.52 |
52-Week Low | $82.57 | $85.86 |
Enterprise Value | $193.69B | $35.05B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BIDU trades at $112.09, down 1.07% today, with a neutral technical signal and bearish moving averages. Recent earnings show a Q1 2026 miss after two consecutive beats, while revenue declined to $129.08B in 2025. The stock holds a strong buy consensus from analysts with a $177.50 price target, supported by AI-driven optimism including Kunlunxin's potential $50B Hong Kong IPO reported by Reuters on June 28, 2026.
BIDU presents a high-risk, high-reward opportunity with its AI pivot accelerating but facing profitability pressures. The 78.19 P/E ratio suggests premium valuation, yet net margins compressed to 1.02% in 2025. Key risks include regulatory scrutiny and competitive threats, while institutional sentiment remains bullish with 75% buy ratings. Upside hinges on AI monetization offsetting legacy search declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →
